Form 4: Sangamo Therapeutics Executive Reports Share Disposition for Tax Obligations
SEC Form 4 Filing
Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of shares to cover tax obligations related to vested restricted stock units.
Summary
- On April 22, 2025, Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, disposed of 6,708 shares of common stock at a price of $0.7763 per share to cover tax obligations.
- This transaction was related to the vesting of a portion of a restricted stock unit (RSU) grant.
- The shares were surrendered to the issuer for mandatory tax withholding purposes.
- Following the transaction, Davis beneficially owns 209,376 shares of Sangamo Therapeutics common stock.
- These holdings include shares from previous RSU grants that vest in quarterly installments through January 2026 and February 2026, subject to continued service.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, with no inherent positive or negative implications for the company's overall outlook.
Future Outlook
The reporting person's remaining RSU grants will continue to vest in quarterly installments through January and February 2026, subject to continued service.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| January 22, 2024 | Date of RSU grant, a portion of which vested on April 22, 2025. |
| February 24, 2023 | Date of RSU grant that will vest in successive equal quarterly installments through February 24, 2026. |
| February 25, 2025 | Date of RSU grant that will vest as to one-fourth (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. |
| April 22, 2025 | Date of transaction: Disposition of shares for tax withholding related to RSU vesting. |
| April 24, 2025 | Date of Form 4 filing. |
| January 22, 2026 | Date through which remaining shares from the January 22, 2024 RSU grant will vest in successive equal quarterly installments. |
| February 24, 2026 | Date through which shares from the February 24, 2023 RSU grant will vest in successive equal quarterly installments. |
| February 25, 2026 | Date on which one-fourth (1/4) of the shares from the February 25, 2025 RSU grant will vest. |
Keywords
Form 4, Sangamo Therapeutics, SGMO, Gregory D. Davis, Restricted Stock Units, RSU, Tax Withholding, Beneficial Ownership, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.